Maculopathy as a Complication of Blood-Brain Barrier Disruption in Patients with Central Nervous System Lymphoma

Anat Galor, Sandra J. Ference, Arun D. Singh, Michael S. Lee, Glen H J Stevens, Victor L Perez Quinones, David M. Peereboom

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Purpose: To report on the development of visually significant maculopathy associated with blood-brain barrier disruption (BBBD) therapy for the treatment of central nervous system (CNS) lymphoma. Design: Retrospective case series. Methods: Chart review of 20 patients undergoing BBBD therapy for treatment of CNS lymphoma at the Cleveland Clinic. Patients with documented maculopathy were included in analysis. Results: Seven (54%) of 13 patients were identified with new macular retinal pigment epithelium (RPE) changes after BBBD treatment. The RPE changes consisted of fine clumps of hyperpigmentation in the foveal region associated with variable degrees of RPE loss. These changes were bilateral but often asymmetric. Two patients had decreased visual acuity resulting from maculopathy. One patient had documented progression of maculopathy after completion of treatment. Conclusions: Maculopathy is a frequent finding after BBBD therapy for CNS lymphoma.

Original languageEnglish
JournalAmerican Journal of Ophthalmology
Volume144
Issue number1
DOIs
StatePublished - Jul 1 2007
Externally publishedYes

Fingerprint

Blood-Brain Barrier
Lymphoma
Central Nervous System
Retinal Pigment Epithelium
Therapeutics
Hyperpigmentation
Visual Acuity

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Maculopathy as a Complication of Blood-Brain Barrier Disruption in Patients with Central Nervous System Lymphoma. / Galor, Anat; Ference, Sandra J.; Singh, Arun D.; Lee, Michael S.; Stevens, Glen H J; Perez Quinones, Victor L; Peereboom, David M.

In: American Journal of Ophthalmology, Vol. 144, No. 1, 01.07.2007.

Research output: Contribution to journalArticle

Galor, Anat ; Ference, Sandra J. ; Singh, Arun D. ; Lee, Michael S. ; Stevens, Glen H J ; Perez Quinones, Victor L ; Peereboom, David M. / Maculopathy as a Complication of Blood-Brain Barrier Disruption in Patients with Central Nervous System Lymphoma. In: American Journal of Ophthalmology. 2007 ; Vol. 144, No. 1.
@article{3f74e66f574348e491667ef6cf6e3975,
title = "Maculopathy as a Complication of Blood-Brain Barrier Disruption in Patients with Central Nervous System Lymphoma",
abstract = "Purpose: To report on the development of visually significant maculopathy associated with blood-brain barrier disruption (BBBD) therapy for the treatment of central nervous system (CNS) lymphoma. Design: Retrospective case series. Methods: Chart review of 20 patients undergoing BBBD therapy for treatment of CNS lymphoma at the Cleveland Clinic. Patients with documented maculopathy were included in analysis. Results: Seven (54{\%}) of 13 patients were identified with new macular retinal pigment epithelium (RPE) changes after BBBD treatment. The RPE changes consisted of fine clumps of hyperpigmentation in the foveal region associated with variable degrees of RPE loss. These changes were bilateral but often asymmetric. Two patients had decreased visual acuity resulting from maculopathy. One patient had documented progression of maculopathy after completion of treatment. Conclusions: Maculopathy is a frequent finding after BBBD therapy for CNS lymphoma.",
author = "Anat Galor and Ference, {Sandra J.} and Singh, {Arun D.} and Lee, {Michael S.} and Stevens, {Glen H J} and {Perez Quinones}, {Victor L} and Peereboom, {David M.}",
year = "2007",
month = "7",
day = "1",
doi = "10.1016/j.ajo.2007.03.057",
language = "English",
volume = "144",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",
number = "1",

}

TY - JOUR

T1 - Maculopathy as a Complication of Blood-Brain Barrier Disruption in Patients with Central Nervous System Lymphoma

AU - Galor, Anat

AU - Ference, Sandra J.

AU - Singh, Arun D.

AU - Lee, Michael S.

AU - Stevens, Glen H J

AU - Perez Quinones, Victor L

AU - Peereboom, David M.

PY - 2007/7/1

Y1 - 2007/7/1

N2 - Purpose: To report on the development of visually significant maculopathy associated with blood-brain barrier disruption (BBBD) therapy for the treatment of central nervous system (CNS) lymphoma. Design: Retrospective case series. Methods: Chart review of 20 patients undergoing BBBD therapy for treatment of CNS lymphoma at the Cleveland Clinic. Patients with documented maculopathy were included in analysis. Results: Seven (54%) of 13 patients were identified with new macular retinal pigment epithelium (RPE) changes after BBBD treatment. The RPE changes consisted of fine clumps of hyperpigmentation in the foveal region associated with variable degrees of RPE loss. These changes were bilateral but often asymmetric. Two patients had decreased visual acuity resulting from maculopathy. One patient had documented progression of maculopathy after completion of treatment. Conclusions: Maculopathy is a frequent finding after BBBD therapy for CNS lymphoma.

AB - Purpose: To report on the development of visually significant maculopathy associated with blood-brain barrier disruption (BBBD) therapy for the treatment of central nervous system (CNS) lymphoma. Design: Retrospective case series. Methods: Chart review of 20 patients undergoing BBBD therapy for treatment of CNS lymphoma at the Cleveland Clinic. Patients with documented maculopathy were included in analysis. Results: Seven (54%) of 13 patients were identified with new macular retinal pigment epithelium (RPE) changes after BBBD treatment. The RPE changes consisted of fine clumps of hyperpigmentation in the foveal region associated with variable degrees of RPE loss. These changes were bilateral but often asymmetric. Two patients had decreased visual acuity resulting from maculopathy. One patient had documented progression of maculopathy after completion of treatment. Conclusions: Maculopathy is a frequent finding after BBBD therapy for CNS lymphoma.

UR - http://www.scopus.com/inward/record.url?scp=34250764922&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250764922&partnerID=8YFLogxK

U2 - 10.1016/j.ajo.2007.03.057

DO - 10.1016/j.ajo.2007.03.057

M3 - Article

C2 - 17601426

AN - SCOPUS:34250764922

VL - 144

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

IS - 1

ER -